SEC Filing Summary: Cerecor Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Cerecor Inc. on May 13, 2021. The filing serves to announce the company's financial results for the quarter ended March 31, 2021. The registrant is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol CERC. Note: The input metadata referenced "Avalo Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes
The filing does not provide specific data regarding material changes versus the prior comparable period. It solely references the issuance of a press release containing the quarterly results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor subject to the liabilities of that section, except as expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed in the body of this 8-K.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 13, 2021).
- Confirm the discrepancy between the metadata company name ("Avalo Therapeutics, Inc.") and the actual registrant ("Cerecor Inc.") to ensure the correct entity is being analyzed.
- Review the full press release for any forward-looking statements or clinical trial updates not summarized in this 8-K.